Progress in the management of Alzheimer's disease.
As the population of the United States continues to age, age-related diseases such as Alzheimer's, the most common form of dementia, pose an increasing clinical challenge. The diagnosis of Alzheimer's disease hinges on the evaluation of cognitive function. Management options are expanding and include new cholinesterase inhibitors, cholinergic agonists, antioxidants, monoamine oxidase inhibitors, and estrogen.
Smith
A L
AL
Case Western Reserve University, Cleveland, USA.
Whitehouse
P J
PJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000235:genetics / Q000473:pathology / Q000523:psychology / Q000628:therapy*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003071:Cognition; D006801:Humans; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010166:Palliative Care; D014055:Tomography, Emission-Computed
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents